We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ABDX market cap is 18.84M. The company's latest EPS is GBP -0.0052 and P/E is -14.90.
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 5.24M | 11.62M | 2.84M | 4.05M | 6.14M |
| Operating Income | -3.31M | -6.46M | -20.84M | -3.56M | -1.34M |
| Net Income | -3.37M | -6.97M | -21.26M | -3.47M | -1.27M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 10.97M | 33.23M | 12.77M | 6.11M | 5.09M |
| Total Liabilities | 8.22M | 11.9M | 6.34M | 3.14M | 2.84M |
| Total Equity | 2.75M | 21.33M | 6.43M | 2.97M | 2.25M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | 2.1M | -12.88M | -7.74M | 913k | -1.66M |
| Investing | -1.94M | -7.28M | -756k | -67k | -23k |
| Financing | 3.37M | 20.74M | 5.92M | -7k | -114k |
| Market Cap | 18.84M |
| Price to Earnings Ratio | -14.90 |
| Price to Sales Ratio | 3.08 |
| Price to Cash Ratio | 13.14 |
| Price to Book Ratio | 8.38 |
| Dividend Yield | - |
| Shares Outstanding | 243.11M |
| Average Volume (1 week) | 140.12k |
| Average Volume (1 Month) | 174.72k |
| 52 Week Change | -29.55% |
| 52 Week High | 12.50 |
| 52 Week Low | 6.75 |
| Spread (Intraday) | 0.5 (6.25%) |
| Company Name | Abingdon Health Plc |
| Address |
york biotech campus york YO41 1LZ |
| Website | https://www.abingdonhealth.com |
| Industry | chemicals & chem preps, nec (2899) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
